Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Research & Development (2020 - 2025)

Insight Molecular Diagnostics' Research & Development history spans 6 years, with the latest figure at $3.9 million for Q3 2025.

  • For Q3 2025, Research & Development rose 37.66% year-over-year to $3.9 million; the TTM value through Sep 2025 reached $12.3 million, up 21.83%, while the annual FY2024 figure was $9.8 million, 5.86% up from the prior year.
  • Research & Development for Q3 2025 was $3.9 million at Insight Molecular Diagnostics, up from $3.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.6 million in Q2 2022 and bottomed at -$4.0 million in Q4 2021.
  • The 5-year median for Research & Development is $2.5 million (2024), against an average of $2.4 million.
  • The largest annual shift saw Research & Development plummeted 322.5% in 2021 before it surged 134.41% in 2022.
  • A 5-year view of Research & Development shows it stood at -$4.0 million in 2021, then surged by 134.41% to $1.4 million in 2022, then soared by 84.83% to $2.5 million in 2023, then dropped by 11.39% to $2.3 million in 2024, then soared by 71.82% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Research & Development are $3.9 million (Q3 2025), $3.3 million (Q2 2025), and $2.9 million (Q1 2025).